Entera Bio Ltd. Ordinary Shares
ENTXEntera Bio Ltd. (ENTX) is a biopharmaceutical company focused on developing oral biologic therapies for serious medical conditions. Leveraging its proprietary platform, the company aims to deliver biologic drugs that can be administered orally, offering potential advantages over traditional injectable treatments. Entera Bio’s pipeline includes candidates targeting osteoporosis, hormone deficiencies, and other indications, with an emphasis on improving patient compliance and convenience.
Company News
Entera Bio's CEO will participate in the Evercore ISI Healthcare Conference, highlighting the company's progress in developing oral peptide therapies for conditions like osteoporosis and hypoparathyroidism.
Entera Bio reported better-than-expected Q2 2025 earnings with a GAAP EPS of $0.06, secured FDA regulatory concurrence for EB613's Phase 3 trial, and maintained a strong cash position of $18.8 million to support operations through mid-Q3 2026.
OPKO Health, Inc. and Entera Bio Ltd. announced that OPKO's ModeX Therapeutics division has formed a Scientific Advisory Board with leaders in immunology and oncology drug development. Additionally, OPKO and Entera's first-in-class dual GLP-1/Glucagon tablet candidate for obesity and metabolic disorders has been selected for presentation at the E...
OPKO Health and Entera Bio have entered into a collaboration agreement to advance an oral GLP-1/Glucagon dual agonist tablet into clinical trials for the treatment of obesity and metabolic disorders.
AbbVie (ABBV) announces that the EMA's CHMP issued a positive opinion on its regulatory filing seeking label expansion for the immunology drug, Skyrizi, to treat UC.
